```
fetch('http://localhost:8000/api/visualize/e6acb80f-833b-461f-9652-417acae9d90d', {
  headers: {
    'Api-Key': 'bedrock1234'
  }
})
```

```
{
  "metadata": {
    "documentsAnalyzed": 20,
    "processingTime": 39351,
    "filesReferenced": 15
  },
  "summary": "This dashboard provides key insights into Medicare Part D drug pricing, utilization trends, and therapeutic market dynamics based on detailed cost data and prescriber analytics.",
  "visualizations": [
    {
      "chartData": {
        "labels": [
          "Oncology",
          "Immunology",
          "Neurology",
          "Cardiovascular",
          "Diabetes",
          "Respiratory"
        ],
        "datasets": [
          {
            "backgroundColor": [
              "#FF6384",
              "#36A2EB",
              "#FFCE56",
              "#4BC0C0",
              "#9966FF",
              "#F97100"
            ],
            "borderColor": "#000000",
            "label": "Average Drug Cost",
            "data": [
              4832,
              3415,
              2847,
              211,
              78,
              624
            ],
            "fill": true
          }
        ]
      },
      "insights": [
        "Oncology drugs had the highest average cost per prescription at $4,832, likely due to specialty medications and novel therapies.",
        "Diabetes drugs had a relatively low average cost of $78 per prescription, indicating higher utilization of generic and low-cost treatments.",
        "Cardiovascular drugs exhibited moderate average costs at $211 per prescription, reflecting a mix of branded and generic medications."
      ],
      "chartType": "bar",
      "description": "Visualizes the average Medicare Part D drug costs across major therapeutic categories for the latest reporting period.",
      "id": "viz1",
      "title": "Average Medicare Drug Costs by Therapeutic Category",
      "recommendations": [
        "Closely monitor high-cost therapeutic areas like oncology for cost-containment opportunities and value-based contracting.",
        "Evaluate therapeutic substitution programs for categories with low-cost generic alternatives like diabetes."
      ]
    },
    {
      "chartData": {
        "labels": [
          "2019",
          "2020",
          "2021",
          "2022",
          "2023"
        ],
        "datasets": [
          {
            "borderColor": "#FF6384",
            "label": "MAPD Plans",
            "data": [
              78,
              82,
              86,
              89,
              92
            ],
            "fill": false
          },
          {
            "borderColor": "#36A2EB",
            "label": "PDPs",
            "data": [
              93,
              108,
              112,
              104,
              102
            ],
            "fill": false
          }
        ]
      },
      "insights": [
        "Average drug costs for MAPD plans have increased steadily from $78 to $92 per prescription over the past 5 years.",
        "PDP drug costs show higher volatility, peaking at $112 in 2021 before dropping to $102 in the latest period.",
        "The cost differential between MAPD and PDP plans has narrowed in recent years as PDPs implemented tighter cost controls."
      ],
      "chartType": "line",
      "description": "Depicts the year-over-year trend in average Medicare Part D drug costs for Medicare Advantage Prescription Drug (MAPD) plans vs. stand-alone Prescription Drug Plans (PDPs).",
      "id": "viz2",
      "title": "Medicare Drug Cost Trends by Plan Type",
      "recommendations": [
        "Analyze drivers behind the divergent cost trends for MAPD vs. PDP plans to identify best practices.",
        "Implement targeted cost management initiatives for high-growth therapeutic areas in MAPD plans."
      ]
    },
    {
      "chartData": {
        "labels": [
          "Part D Plan Paid",
          "Beneficiary Cost-Share"
        ],
        "datasets": [
          {
            "data": [
              75,
              25
            ],
            "backgroundColor": [
              "#36A2EB",
              "#FF6384"
            ]
          }
        ]
      },
      "insights": [
        "Medicare Part D plans cover 75% of total drug costs for beneficiaries.",
        "Beneficiary cost-sharing accounts for the remaining 25% of drug expenditures.",
        "Low-income subsidies and Medicare reinsurance provisions help limit out-of-pocket costs for beneficiaries."
      ],
      "chartType": "pie",
      "description": "Shows the distribution of total drug costs borne by Medicare beneficiaries through out-of-pocket expenditures vs. costs covered by Medicare Part D plans.",
      "id": "viz3",
      "title": "Medicare Beneficiary Cost-Sharing Breakdown",
      "recommendations": [
        "Promote Medicare Part D enrollment and low-income subsidies to reduce beneficiary out-of-pocket burden.",
        "Develop patient support programs to assist with cost-sharing obligations for high-cost specialty drugs."
      ]
    },
    {
      "chartData": {
        "labels": [
          "Opioids",
          "Long-Acting Opioids",
          "Antibiotics",
          "Antipsychotics",
          "Other Drug Classes"
        ],
        "datasets": [
          {
            "backgroundColor": "rgba(54, 162, 235, 0.2)",
            "borderColor": "#36A2EB",
            "label": "High-Volume Prescribers",
            "data": [
              3.2,
              4.9,
              4.6,
              5.1,
              3.8
            ],
            "fill": true
          }
        ]
      },
      "insights": [
        "High-volume prescribers show lower relative utilization for opioids compared to other drug classes.",
        "However, utilization of long-acting opioids is higher than average for this subset of prescribers.",
        "Antibiotics and antipsychotics in the elderly also exhibit above-average utilization by these prescribers."
      ],
      "chartType": "radar",
      "description": "Radar chart depicting prescribing patterns for opioids and long-acting opioids relative to other drug classes for high-volume prescribers.",
      "id": "viz4",
      "title": "Prescriber Analysis - Opioid Utilization",
      "recommendations": [
        "Implement prescriber education on opioid risk evaluation and mitigation strategies (REMS) programs.",
        "Identify high-utilization prescribers for long-acting opioids and antipsychotics for targeted intervention."
      ]
    }
  ],
  "createdAt": "2025-07-10T13:19:41.185Z",
  "description": "Comprehensive analysis of healthcare commercial intelligence data",
  "id": "e6acb80f-833b-461f-9652-417acae9d90d",
  "title": "Healthcare Data Insights Dashboard"
}
```



```
fetch('http://localhost:8000/api/visualize/generate', {
  method: 'POST',
  headers: {
    'Api-Key': 'bedrock1234'
  }
})
```

```
{
  "visualizationSetId": "e6acb80f-833b-461f-9652-417acae9d90d",
  "title": "Healthcare Data Insights Dashboard",
  "summary": "This dashboard provides key insights into Medicare Part D drug pricing, utilization trends, and therapeutic market dynamics based on detailed cost data and prescriber analytics.",
  "visualizationCount": 4,
  "createdAt": "2025-07-10T13:19:41.185Z",
  "metadata": {
    "documentsAnalyzed": 20,
    "filesReferenced": 15,
    "processingTime": 39351
  }
}
```


```
fetch('http://localhost:8000/api/visualize', {
  headers: {
    'Api-Key': 'bedrock1234'
  }
})
```

```
{
  "visualizationSets": [
    {
      "createdAt": "2025-07-10T13:19:41.185Z",
      "metadata": {
        "documentsAnalyzed": 20,
        "processingTime": 39351,
        "filesReferenced": 15
      },
      "summary": "This dashboard provides key insights into Medicare Part D drug pricing, utilization trends, and therapeutic market dynamics based on detailed cost data and prescriber analytics.",
      "id": "e6acb80f-833b-461f-9652-417acae9d90d",
      "title": "Healthcare Data Insights Dashboard",
      "visualizations": [
        {
          "chartType": "bar"
        }
      ]
    }
  ],
  "count": 1
}
```